ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Age-stratified prevalence of anti-hepatitis A virus antibodies in four metropolitan Indian cities and recent changes in Pune city.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical Guidelines for Hepatitis E Vaccination in India: An Expert Panel Consensus Report on the Recombinant Hepatitis E Vaccine, HEV 239.Pathogens (Basel, Switzerland) · 2026Review
- Shifting epidemiology and disease severity: Rethinking India's hepatitis A strategy in the context of acute liver failure.Journal of family medicine and primary care · 2026Article
- Seroprevalence of IgG antibodies against hepatitis-A infection among individuals aged 6-30 years in India, 2021: a nationwide population-based cross-sectional study.The Lancet regional health. Southeast Asia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectivesPune, western India, was earlier identified as hyperendemic for hepatitis A. Subsequently, we noted age and socio-economic status-dependent reduction in hepatitis A virus (HAV) prevalence. To assess the situation in different parts of India, this multicentric, hospital-based, cross-sectional study was conducted in four metropolitan cities in the northern/southern/eastern/western regions.
methodsAs per age group-anti-HAV-positivity-specific sample size calculations (1-40 years), 496 samples/centre were collected from Pune, Kolkata, Chennai and Ludhiana. All samples were tested for anti-HAV antibodies using enzyme-linked immunosorbent assay (ELISA).
resultsOverall, 44.9% of children up to five years of age were anti-HAV antibody-positive (ELISA), with a steady increase reaching 92.9% by the age of 26-40 years. Importantly, 782/1756 (44.5%) of the total population ≤ 15 years was anti-HAV negative and hence susceptible to HAV. The city-wise analysis documented similar patterns with a few differences. According to the World Health Organization (WHO) classification of HAV endemicity, Pune, Chennai and Ludhiana were classified as cities with intermediate endemicity, whereas Kolkata with lower seroprevalence had low endemicity. Compared to the 2011-2012 survey anti-HAV positivity remained unchanged in the other cities except for the rise in Chennai. Apart from age, other risk factors varied in different cities. A comparison of socio-economic-dependent, age-stratified serosurveys conducted during 1982, 1992, 1998, 2017 and 2022 in Pune documented the shift from high to intermediate endemicity in the population with high socio-economic status in 1998 and lower-middle socio-economic strata in 2017.
conclusionThe lowering of anti-HAV positivity reflects a definite improvement in sanitation and voluntary vaccination, but seems to have slowed down during recent years. Additional, well-defined efforts are necessary.
Indexed as
Identifiers
40053056What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.